1
|
Mansour OC, Nudelman A, Rephaeli A, Phillips DR, Cutts SM, Evison BJ. An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells. Cancer Chemother Pharmacol 2022; 89:773-784. [PMID: 35460360 DOI: 10.1007/s00280-022-04435-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 04/02/2022] [Indexed: 11/29/2022]
Abstract
PURPOSE Pixantrone is a synthetic aza-anthracenedione currently used in the treatment of non-Hodgkin's lymphoma. The drug is firmly established as a poison of the nuclear enzyme topoisomerase II, however, pixantrone can also generate covalent drug-DNA adducts following activation by formaldehyde. While pixantrone-DNA adducts form proficiently in vitro, little evidence is presently at hand to indicate their existence within cells. The molecular nature of these lesions within cancer cells exposed to pixantrone and formaldehyde-releasing prodrugs was characterized along with the cellular responses to their formation. METHODS In vitro crosslinking assays, [14C] scintillation counting analyses and alkaline comet assays were applied to characterize pixantrone-DNA adducts. Flow cytometry, cell growth inhibition and clonogenic assays were used to measure cancer cell kill and survival. RESULTS Pixantrone-DNA adducts were not detectable in MCF-7 breast cancer cells exposed to [14C] pixantrone (10-40 µM) alone, however the addition of the formaldehyde-releasing prodrug AN9 yielded readily measurable levels of the lesion at ~ 1 adduct per 10 kb of genomic DNA. Co-administration with AN9 completely reversed topoisomerase II-associated DNA damage induction by pixantrone yet potentiated cell kill by the drug, suggesting that pixantrone-DNA adducts may promote a topoisomerase II-independent mechanism of cell death. Pixantrone-DNA adduct-forming treatments generally conferred mild synergism in multiple cell lines in various cell death and clonogenic assays, while pixantrone analogues either incapable or relatively defective in forming DNA adducts demonstrated antagonism when combined with AN9. CONCLUSIONS The features unique to pixantrone-DNA adducts may be leveraged to enhance cancer cell kill and may be used to guide the design of pixantrone analogues that generate adducts with more favorable anticancer properties.
Collapse
Affiliation(s)
- Oula C Mansour
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia
| | - Abraham Nudelman
- Chemistry Department, Bar-Ilan University, 52900, Ramat-Gan, Israel
| | - Ada Rephaeli
- Sackler Faculty of Medicine, Felsenstein Medical Research Center, Tel-Aviv University, 49100, Petach-Tikva, Israel
| | - Don R Phillips
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia
| | - Suzanne M Cutts
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia.
| | - Benny J Evison
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia.
- Nyrada Inc, Suite 2, Level 3, 828 Pacific Highway, Gordon, NSW, 2072, Australia.
| |
Collapse
|
2
|
Medan J, Sleebs BE, Lackovic K, Watson KG, Evison BJ, Phillips DR, Cutts SM. Development of an automated assay for accelerated in vitro detection of DNA adduct-inducing and crosslinking agents. Bioorg Med Chem Lett 2021; 35:127813. [PMID: 33486050 DOI: 10.1016/j.bmcl.2021.127813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 12/21/2020] [Accepted: 01/17/2021] [Indexed: 10/22/2022]
Abstract
Current techniques for the identification of DNA adduct-inducing and DNA interstrand crosslinking agents include electrophoretic crosslinking assays, electrophoretic gel shift assays, DNA and RNA stop assays, mass spectrometry-based methods and 32P-post-labelling. While these assays provide considerable insight into the site and stability of the interaction, they are relatively expensive, time-consuming and sometimes rely on the use of radioactively-labelled components, and thus are ill-suited to screening large numbers of compounds. A novel medium throughput assay was developed to overcome these limitations and was based on the attachment of a biotin-tagged double stranded (ds) oligonucleotide to Corning DNA-Bind plates. We aimed to detect anthracycline and anthracenedione DNA adducts which form by initial non-covalent intercalation with duplex DNA, and subsequent covalent adduct formation which is mediated by formaldehyde. Following drug treatment, DNA samples were subjected to a denaturation step, washing and then measurement by fluorescence to detect remaining drug-DNA species using streptavidin-europium. This dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) is a time-resolved fluorescence intensity assay where the fluorescence signal arises only from stabilised drug-DNA complexes. We applied this new methodology to the identification of anthracycline-like compounds with the ability to functionally crosslink double-strand oligonucleotides. The entire procedure can be performed by robotics, requiring low volumes of compounds and reagents, thereby reducing costs and enabling multiple compounds to be assessed on a single microtitre plate.
Collapse
Affiliation(s)
- Jelena Medan
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia; Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia
| | - Brad E Sleebs
- Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia
| | - Kurt Lackovic
- Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia; Cancer Trials Australia, Melbourne, Victoria 3000, Australia
| | - Keith G Watson
- Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia
| | - Benny J Evison
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia; Nyrada Inc, 828 Pacific Highway, Gordon, NSW 2072, Australia
| | - Don R Phillips
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia
| | - Suzanne M Cutts
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia.
| |
Collapse
|
3
|
Pumuye PP, Evison BJ, Konda SK, Collins JG, Kelso C, Medan J, Sleebs BE, Watson K, Phillips DR, Cutts SM. Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. Bioorg Med Chem 2020; 28:115260. [PMID: 31870833 DOI: 10.1016/j.bmc.2019.115260] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 12/05/2019] [Accepted: 12/09/2019] [Indexed: 12/17/2022]
Abstract
Mitoxantrone is an anticancer anthracenedione that can be activated by formaldehyde to generate covalent drug-DNA adducts. Despite their covalent nature, these DNA lesions are relatively labile. It was recently established that analogues of mitoxantrone featuring extended side-chains terminating in primary amino groups typically yielded high levels of stable DNA adducts following their activation by formaldehyde. In this study we describe the DNA sequence-specific binding properties of the mitoxantrone analogue WEHI-150 which is the first anthracenedione to form apparent DNA crosslinks mediated by formaldehyde. The utility of this compound lies in the versatility of the covalent binding modes displayed. Unlike other anthracenediones described to date, WEHI-150 can mediate covalent adducts that are independent of interactions with the N-2 of guanine and is capable of adduct formation at novel DNA sequences. Moreover, these covalent adducts incorporate more than one formaldehyde-mediated bond with DNA, thus facilitating the formation of highly lethal DNA crosslinks. The versatility of binding observed is anticipated to allow the next generation of anthracenediones to interact with a broader spectrum of nucleic acid species than previously demonstrated by the parent compounds, thus allowing for more diverse biological activities.
Collapse
Affiliation(s)
- Paul P Pumuye
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia
| | - Benny J Evison
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia
| | - Shyam K Konda
- School of Science, University of New South Wales, Canberra 2610, Australia
| | - J Grant Collins
- School of Science, University of New South Wales, Canberra 2610, Australia
| | - Celine Kelso
- School of Chemistry, University of Wollongong, Wollongong, NSW 2522, Australia
| | - Jelena Medan
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia; Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia
| | - Brad E Sleebs
- Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia
| | - Keith Watson
- Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia
| | - Don R Phillips
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia
| | - Suzanne M Cutts
- La Trobe Institute for Molecular Science, La Trobe University, Victoria 3086, Australia.
| |
Collapse
|
4
|
Al-Aamri HM, Ku H, Irving HR, Tucci J, Meehan-Andrews T, Bradley C. Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia. BMC Cancer 2019; 19:179. [PMID: 30813936 PMCID: PMC6391779 DOI: 10.1186/s12885-019-5377-y] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Accepted: 02/18/2019] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Daunorubicin is commonly used in the treatment of acute lymphoblastic leukaemia (ALL). The aim of this study was to explore the kinetics of double strand break (DSB) formation of three ALL cell lines following exposure to daunorubicin and to investigate the effects of daunorubicin on the cell cycle and the protein kinases involved in specific checkpoints following DNA damage and recovery periods. METHODS Three ALL cell lines CCRF-CEM and MOLT-4 derived from T lymphocytes and SUP-B15 derived from B lymphocytes were examined following 4 h treatment with daunorubicin chemotherapy and 4, 12 and 24 h recovery periods. Cell viability was measured via MTT (3-(4,5-dimethylthiazol-2-yl)-2-5 diphenyltetrazolium bromide) assay, reactive oxygen species (ROS) production by flow cytometry, double stranded DNA breaks by detecting γH2AX levels while stages of the cell cycle were detected following propidium iodide staining and flow cytometry. Western blotting was used to detect specific proteins while RNA was extracted from all cell lines and converted to cDNA to sequence Ataxia-telangiectasia mutated (ATM). RESULTS Daunorubicin induced different degrees of toxicity in all cell lines and consistently generated reactive oxygen species. Daunorubicin was more potent at inducing DSB in MOLT-4 and CCRF-CEM cell lines while SUP-B15 cells showed delays in DSB repair and significantly more resistance to daunorubicin compared to the other cell lines as measured by γH2AX assay. Daunorubicin also causes cell cycle arrest in all three cell lines at different checkpoints at different times. These effects were not due to mutations in ATM as sequencing revealed none in any of the three cell lines. However, p53 was phosphorylated at serine 15 only in CCRF-CEM and MOLT-4 but not in SUP-B15 cells. The lack of active p53 may be correlated to the increase of SOD2 in SUP-B15 cells. CONCLUSIONS The delay in DSB repair and lower sensitivity to daunorubicin seen in the B lymphocyte derived SUP-B15 cells could be due to loss of function of p53 that may be correlated to increased expression of SOD2 and lower ROS production.
Collapse
Affiliation(s)
- Hussain Mubarak Al-Aamri
- Department of Pharmacy and Applied Sciences, La Trobe Institute for Molecular Science (LIMS), La Trobe University, P.O. Box 199, Bendigo, Victoria, Australia
| | - Heng Ku
- Department of Pharmacy and Applied Sciences, La Trobe Institute for Molecular Science (LIMS), La Trobe University, P.O. Box 199, Bendigo, Victoria, Australia
| | - Helen R Irving
- Department of Pharmacy and Applied Sciences, La Trobe Institute for Molecular Science (LIMS), La Trobe University, P.O. Box 199, Bendigo, Victoria, Australia.
| | - Joseph Tucci
- Department of Pharmacy and Applied Sciences, La Trobe Institute for Molecular Science (LIMS), La Trobe University, P.O. Box 199, Bendigo, Victoria, Australia
| | - Terri Meehan-Andrews
- Department of Pharmacy and Applied Sciences, La Trobe Institute for Molecular Science (LIMS), La Trobe University, P.O. Box 199, Bendigo, Victoria, Australia
| | - Christopher Bradley
- Department of Pharmacy and Applied Sciences, La Trobe Institute for Molecular Science (LIMS), La Trobe University, P.O. Box 199, Bendigo, Victoria, Australia
| |
Collapse
|
5
|
Minotti G, Han H, Cattan V, Egorov A, Bertoni F. Pixantrone: novel mode of action and clinical readouts. Expert Rev Hematol 2018; 11:587-596. [DOI: 10.1080/17474086.2018.1476848] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Giorgio Minotti
- Department of Medicine and Unit for Drug Sciences, University Campus Bio-Medico, Rome, Italy
| | - Haiyong Han
- Molecular Medicine Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Valérie Cattan
- R&D Oncology, Institut de Recherches Internationales Servier, Suresnes, France
| | - Anton Egorov
- R&D Oncology, Institut de Recherches Internationales Servier, Suresnes, France
| | - Francesco Bertoni
- Istituto Oncologico di Ricerca, Università della Svizzera italiana, Bellinzona, Switzerland
- Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| |
Collapse
|
6
|
Konda SK, Wang H, Cutts SM, Phillips DR, Collins JG. Binding of pixantrone to DNA at CpA dinucleotide sequences and bulge structures. Org Biomol Chem 2016; 13:5972-82. [PMID: 25929194 DOI: 10.1039/c5ob00526d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The binding of the anti-cancer drug pixantrone to three oligonucleotide sequences, d(TCATATGA)2, d(CCGAGAATTCCGG)2 {double bulge = DB} and the non-self complementary d(TACGATGAGTA) : d(TACCATCGTA) {single bulge = SB}, has been studied by NMR spectroscopy and molecular modelling. The upfield shifts observed for the aromatic resonances of pixantrone upon addition of the drug to each oligonucleotide confirmed the drug bound by intercalation. For the duplex sequence d(TCATATGA)2, NOEs were observed from the pixantrone aromatic H7/8 and aliphatic Ha/Hb protons to the H6/H8 and H1' protons of the C2, A3, T6 and G7 nucleotides, demonstrating that pixantrone preferentially binds at the symmetric CpA sites. However, weaker NOEs observed to various protons from the T4 and A5 residues indicated alternative minor binding sites. NOEs from the H7/H8 and Ha/Hb protons to both major (H6/H8) and minor groove (H1') protons indicated approximately equal proportions of intercalation was from the major and minor groove at the CpA sites. Intermolecular NOEs were observed between the H7/H8 and H4 protons of pixantrone and the A4H1' and G3H1' protons of the oligonucleotide that contains two symmetrically related bulge sites (DB), indicative of binding at the adenine bulge sites. For the oligonucleotide that only contains a single bulge site (SB), NOEs were observed from pixantrone protons to the SB G7H1', A8H1' and G9H1' protons, confirming that the drug bound selectively at the adenine bulge site. A molecular model of pixantrone-bound SB could be constructed with the drug bound from the minor groove at the A8pG9 site that was consistent with the observed NMR data. The results demonstrate that pixantrone preferentially intercalates at adenine bulge sites, compared to duplex DNA, and predominantly from the minor groove.
Collapse
Affiliation(s)
- Shyam K Konda
- School of Physical, Environmental and Mathematical Sciences, University of New South Wales, Australian Defence Force Academy, Northcott Drive, Campbell, ACT 2600, Australia.
| | | | | | | | | |
Collapse
|
7
|
Konda SK, Kelso C, Pumuye PP, Medan J, Sleebs BE, Cutts SM, Phillips DR, Collins JG. Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA. Org Biomol Chem 2016; 14:4728-38. [DOI: 10.1039/c6ob00561f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The ability of the anthracenedione anticancer drug WEHI-150 to form covalent adducts with DNA, after activation by formaldehyde, has been studied by mass spectrometry, HPLC and NMR spectroscopy.
Collapse
Affiliation(s)
- Shyam K. Konda
- School of Physical
- Environmental and Mathematical Sciences
- University of New South Wales
- Australian Defence Force Academy
- Campbell
| | - Celine Kelso
- School of Chemistry
- University of Wollongong
- Wollongong
- Australia
| | - Paul P. Pumuye
- Biochemistry Department
- La Trobe University
- Bundoora
- Australia
| | - Jelena Medan
- Biochemistry Department
- La Trobe University
- Bundoora
- Australia
- Chemical Biology Division and Infection and Immunity Division
| | - Brad E. Sleebs
- Chemical Biology Division and Infection and Immunity Division
- The Walter and Eliza Hall Institute of Medical Research
- Parkville
- Australia
- Department of Medical Biology
| | | | | | - J. Grant Collins
- School of Physical
- Environmental and Mathematical Sciences
- University of New South Wales
- Australian Defence Force Academy
- Campbell
| |
Collapse
|
8
|
|
9
|
Ankers EA, Evison BJ, Phillips DR, Brownlee RTC, Cutts SM. Design, synthesis, and DNA sequence selectivity of formaldehyde-mediated DNA-adducts of the novel N-(4-aminobutyl) acridine-4-carboxamide. Bioorg Med Chem Lett 2014; 24:5710-5715. [PMID: 25453806 DOI: 10.1016/j.bmcl.2014.10.062] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 10/13/2014] [Accepted: 10/17/2014] [Indexed: 11/30/2022]
Abstract
A novel derivative of the anti-tumor agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) was prepared by reduction of 9-oxoacridan-4-carboxylic acid to acridine-4-carboxylic acid with subsequent conversion to N-(4-aminobutyl)acridine-4-carboxamide (C4-DACA). Molecular modeling studies suggested that a DACA analogue comprising a side chain length of four carbons was optimal to form formaldehyde-mediated drug-DNA adducts via the minor groove. An in vitro transcription assay revealed that formaldehyde-mediated C4-DACA-DNA adducts selectively formed at CpG and CpA dinucleotide sequences, which is strikingly similar to that of formaldehyde-activated anthracenediones such as pixantrone.
Collapse
Affiliation(s)
- Elizabeth A Ankers
- Department of Chemistry, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora 3086, Australia
| | - Benny J Evison
- Department of Biochemistry, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora 3086, Australia; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
| | - Don R Phillips
- Department of Biochemistry, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora 3086, Australia
| | - Robert T C Brownlee
- Department of Chemistry, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora 3086, Australia
| | - Suzanne M Cutts
- Department of Biochemistry, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora 3086, Australia.
| |
Collapse
|
10
|
Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer 2014; 61:922-4. [PMID: 24166988 PMCID: PMC3951603 DOI: 10.1002/pbc.24800] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Accepted: 09/10/2013] [Indexed: 12/21/2022]
Abstract
Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0 nM to 30.0 μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5 mg/kg) administered intravenously using an every 4 day × 3 schedule. In vitro pixantrone showed a median relative IC50 value of 54 nM (range <3 nM to 1.03 μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft.
Collapse
Affiliation(s)
| | | | - Min H. Kang
- Texas Tech University Health Sciences Center, Lubbock, TX
| | | | | | | |
Collapse
|
11
|
To Market, To Market—2012. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2013. [DOI: 10.1016/b978-0-12-417150-3.00028-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/25/2023]
|
12
|
The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts. Cancer Chemother Pharmacol 2012; 71:809-16. [DOI: 10.1007/s00280-012-2049-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Accepted: 12/03/2012] [Indexed: 10/27/2022]
|
13
|
Martinet N, Michel BY, Bertrand P, Benhida R. Small molecules DNAmethyltransferasesinhibitors. MEDCHEMCOMM 2012. [DOI: 10.1039/c1md00194a] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
This review describes current knowledge concerning DNA methyltransferases (DNMT) biology and the two main classes of DNMT inhibtors.
Collapse
Affiliation(s)
- Nadine Martinet
- Laboratoire de Chimie des Molécules Bioactives et des Arômes
- UMR 6001 CNRS
- Institut de Chimie de Nice
- Université de Nice-Sophia Antipolis
- 06108 Nice Cedex 2
| | - Benoît Y. Michel
- Laboratoire de Chimie des Molécules Bioactives et des Arômes
- UMR 6001 CNRS
- Institut de Chimie de Nice
- Université de Nice-Sophia Antipolis
- 06108 Nice Cedex 2
| | - Philippe Bertrand
- Laboratory of reactivity and synthesis of natural substances
- UMR 6514 Poitiers
- France
| | - Rachid Benhida
- Laboratoire de Chimie des Molécules Bioactives et des Arômes
- UMR 6001 CNRS
- Institut de Chimie de Nice
- Université de Nice-Sophia Antipolis
- 06108 Nice Cedex 2
| |
Collapse
|
14
|
Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR, Cutts SM. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe. Biochem Pharmacol 2011; 82:1604-18. [DOI: 10.1016/j.bcp.2011.08.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Revised: 08/10/2011] [Accepted: 08/11/2011] [Indexed: 12/01/2022]
|
15
|
Duong A, Steinmaus C, McHale CM, Vaughan CP, Zhang L. Reproductive and developmental toxicity of formaldehyde: a systematic review. Mutat Res 2011; 728:118-38. [PMID: 21787879 PMCID: PMC3203331 DOI: 10.1016/j.mrrev.2011.07.003] [Citation(s) in RCA: 162] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2011] [Revised: 07/09/2011] [Accepted: 07/09/2011] [Indexed: 11/30/2022]
Abstract
Formaldehyde, the recently classified carcinogen and ubiquitous environmental contaminant, has long been suspected of causing adverse reproductive and developmental effects, but previous reviews were inconclusive, due in part, to limitations in the design of many of the human population studies. In the current review, we systematically evaluated evidence of an association between formaldehyde exposure and adverse reproductive and developmental effects, in human populations and in vivo animal studies, in the peer-reviewed literature. The mostly retrospective human studies provided evidence of an association of maternal exposure with adverse reproductive and developmental effects. Further assessment of this association by meta-analysis revealed an increased risk of spontaneous abortion (1.76, 95% CI 1.20-2.59, p=0.002) and of all adverse pregnancy outcomes combined (1.54, 95% CI 1.27-1.88, p<0.001), in formaldehyde-exposed women, although differential recall, selection bias, or confounding cannot be ruled out. Evaluation of the animal studies including all routes of exposure, doses and dosing regimens studied, suggested positive associations between formaldehyde exposure and reproductive toxicity, mostly in males. Potential mechanisms underlying formaldehyde-induced reproductive and developmental toxicities, including chromosome and DNA damage (genotoxicity), oxidative stress, altered level and/or function of enzymes, hormones and proteins, apoptosis, toxicogenomic and epigenomic effects (such as DNA methylation), were identified. To clarify these associations, well-designed molecular epidemiologic studies, that include quantitative exposure assessment and diminish confounding factors, should examine both reproductive and developmental outcomes associated with exposure in males and females. Together with mechanistic and animal studies, this will allow us to better understand the systemic effect of formaldehyde exposure.
Collapse
Affiliation(s)
- Anh Duong
- School of Public Health, University of California, Berkeley, CA 94720
| | - Craig Steinmaus
- School of Public Health, University of California, Berkeley, CA 94720
- Office of Environmental Health Hazard Assessment, California Environmental Protection Agency; Oakland, CA 94612
| | - Cliona M. McHale
- School of Public Health, University of California, Berkeley, CA 94720
| | - Charles P. Vaughan
- Global Health Sciences, University of California, San Francisco, CA 94143
| | - Luoping Zhang
- School of Public Health, University of California, Berkeley, CA 94720
| |
Collapse
|
16
|
Jamal-Hanjani M, Pettengell R. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Expert Opin Drug Metab Toxicol 2011; 7:1441-8. [DOI: 10.1517/17425255.2011.618834] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
17
|
Borchmann P, Herbrecht R, Wilhelm M, Morschhauser F, Heß G, Cernohous P, Veals SA, Singer JW, Engert A. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2011; 52:620-8. [DOI: 10.3109/10428194.2010.546016] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
18
|
Mansour OC, Evison BJ, Sleebs BE, Watson KG, Nudelman A, Rephaeli A, Buck DP, Collins JG, Bilardi RA, Phillips DR, Cutts SM. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. J Med Chem 2010; 53:6851-66. [PMID: 20860366 DOI: 10.1021/jm901894c] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Mitoxantrone is an anticancer agent that acts as a topoisomerase II poison, however, it can also be activated by formaldehyde to form DNA adducts. Pixantrone, a 2-aza-anthracenedione with terminal primary amino groups in its side chains, forms formaldehyde-mediated adducts with DNA more efficiently than mitoxantrone. Molecular modeling studies indicated that extension of the "linker" region of anthracenedione side arms would allow the terminal primary amino greater flexibility and thus access to the guanine residues on the opposite DNA strand. New derivatives based on the pixantrone and mitoxantrone backbones were synthesized, and these incorporated primary amino groups as well as extended side chains. The stability of DNA adducts increased with increasing side chain length of the derivatives. A mitoxantrone derivative bearing extended side chains (7) formed the most stable adducts with ∼100-fold enhanced stability compared to mitoxantrone. This finding is of great interest because long-lived drug-DNA adducts are expected to perturb DNA-dependent functions at all stages of the cell cycle.
Collapse
Affiliation(s)
- Oula C Mansour
- Department of Biochemistry, La Trobe University, Victoria 3086, Australia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Adnan N, Buck DP, Evison BJ, Cutts SM, Phillips DR, Collins JG. DNA binding by pixantrone. Org Biomol Chem 2010; 8:5359-66. [PMID: 20865205 DOI: 10.1039/c0ob00295j] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The binding of the anticancer drug pixantrone (6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate) to the octanucleotide duplexes d(ACGATCGT)(2) and the corresponding C-5 methylated cytosine ((5Me)C) analogue d(A(5Me)CGAT(5Me)CGT)(2) has been studied by NMR spectroscopy and molecular modelling. The large upfield shifts observed for the resonances from the aromatic protons of pixantrone upon addition to either d(ACGATCGT)(2) or the corresponding (5Me)C analogue is consistent with the drug binding the octanucleotides by intercalation. The selective reduction in the sequential NOEs between the C(2)-G(3) and C(6)-G(7) nucleotides in NOESY spectra of either octanucleotide with added pixantrone confirms the intercalative binding mechanism. Strong NOEs from the side-chain ethylene protons of pixantrone to the H5 protons and the 5-CH(3) protons of the C(2) and C(6) residues of d(ACGATCGT)(2) and d(A(5Me)CGAT(5Me)CGT)(2), respectively, indicate that pixantrone predominantly intercalates from the DNA major groove at the 5'-CG and 5'-(5Me)CG sites. Simple molecular models based on the conclusions from the NMR experiments indicated that the (5Me)C groups do not represent a steric barrier to intercalation from the major groove. However, the observation of weak NOEs from the ethylene protons of pixantrone to a variety of minor groove protons from either octanucleotide suggests that the drug can also associate in the minor groove.
Collapse
Affiliation(s)
- Najia Adnan
- School of Physical, Environmental and Mathematical Sciences University College, University of New South Wales, Australian Defence Force Academy, Northcott Drive, Campbell, ACT 2600, Australia
| | | | | | | | | | | |
Collapse
|
20
|
Mukherji D, Pettengell R. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Expert Opin Pharmacother 2010; 11:1915-23. [DOI: 10.1517/14656566.2010.494180] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
21
|
Evison BJ, Phillips DR, Cutts SM. In vitro transcription assay for resolution of drug-DNA interactions at defined DNA sequences. Methods Mol Biol 2010; 613:207-222. [PMID: 19997886 DOI: 10.1007/978-1-60327-418-0_13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A major class of anticancer agents in current clinical use exerts its anticancer effects by binding covalently or non-covalently to DNA. A detailed understanding of the nature of these drug-DNA complexes would be expected to lead to better uses of these drugs, and also assist with the design of improved drug derivatives. Here, we present a transcriptional footprinting assay that can be implemented to define the DNA sequence specificity and kinetics associated with drug-DNA complexes. The basic steps involve the formation of drug-DNA complexes, the formation of synchronised initiated transcripts, and finally transcriptional elongation to reveal drug blockage sites that impede the progression of RNA polymerase. We have used the "in vitro transcription assay" to investigate many covalent drug-DNA interactions; most notably those obtained using anthracycline anticancer agents such as doxorubicin and anthracenedione-based anticancer agents, including mitoxantrone and pixantrone.
Collapse
Affiliation(s)
- Benny J Evison
- Department of Biochemistry, La Trobe University, Bundoora, VIC, Australia
| | | | | |
Collapse
|
22
|
Evison BJ, Bilardi RA, Chiu FCK, Pezzoni G, Phillips DR, Cutts SM. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res 2009; 37:6355-70. [PMID: 19720735 PMCID: PMC2770666 DOI: 10.1093/nar/gkp700] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
DNA methylation is an epigenetic modification of the mammalian genome that occurs predominantly at cytosine residues of the CpG dinucleotide. Following formaldehyde activation, pixantrone alkylates DNA and particularly favours the CpG motif. Aberrations in CpG methylation patterns are a feature of most cancer types, a characteristic that may determine their susceptibility to specific drug treatments. Given their common target, DNA methylation may modulate the DNA damage induced by formaldehyde-activated pixantrone. In vitro transcription, mass spectrometry and oligonucleotide band shift assays were utilized to establish that pixantrone–DNA adduct formation was consistently enhanced 2–5-fold at discrete methylated CpG doublets. The methylation-mediated enhancement was exquisitely sensitive to the position of the methyl substituent since methylation at neighboring cytosine residues failed to confer an increase in pixantrone–DNA alkylation. Covalent modification of DNA by formaldehyde-activated doxorubicin, but not cisplatin, was augmented by neighbouring CpG methylation, indicating that modulation of binding by CpG methylation is not a general feature of all alkylators. HCT116 colon cancer cells vastly deficient in CpG methylation were 12- and 10-fold more resistant to pixantrone and doxorubicin relative to the wild-type line, suggesting that these drugs may selectively recognize the aberrant CpG methylation profiles characteristic of most tumour types.
Collapse
Affiliation(s)
- Benny J Evison
- Department of Biochemistry, La Trobe University, Victoria 3086
| | | | | | | | | | | |
Collapse
|